Introduction {#s1}
============

Gastric cancer (GC) is the fourth major malignancy and the second dominant cause of cancer-induced death in the world (de Martel et al., [@B5]). In 2017, 28,000 new cases and 10,960 deaths of GC were projected to occur in the United States (Siegel et al., [@B26]). *Helicobacter pylori* infection contributes to causing the progression of chronic inflammation to GC (Fox and Wang, [@B8]). Some studies demonstrated the extremely low risk of developing GC in *H. pylori*- negative subjects (Uemura et al., [@B31]). However, nearly all *H. pylori*-positive subjects have chronic gastritis, and only 1--2% develop to GC. Therefore, other factors such as genetic factors and lifestyle may play important roles in the gastric tumorigenesis (Carcas, [@B3]).

Tumor necrosis factor (TNF)-α belonging to the TNF/TNF receptor cytokine superfamily can be found in plasma or serum of healthy people, as well as some cancer patients (Balkwill, [@B2]). TNF-α production by tumors is related with hormone irresponsiveness, poor prognosis, and cachexia/asthenia (Szlosarek and Balkwill, [@B29]; Tisdale, [@B30]). The TNF-α-blocked experimental mice were resistant to skin and colorectal cancer occurrence (Moore et al., [@B22]; Popivanova et al., [@B24]). (Oshima et al., [@B23]). The TNF-α/TNFR1 signaling could promote GC occurrence by inducing NADPH oxidase organizer 1 (Noxo1) and G protein subunit alpha 14 (GNA14), which are crucial in the tumorigenicity and stemness of GC cells, in tumor cells (Oshima et al., [@B23]). The above observations suggest TNF-α plays important roles in the etiology of GC.

*TNF-*α located in chromosome 2 has four exon counts. The gene contains several polymorphic sites, including the widely-studied *TNF-*α-238 (rs361525) and−308 (rs1800629). Some studies demonstrated the relationship between *TNF-*α rs361525 polymorphism and GC risk (Zambon et al., [@B42]; Xing et al., [@B37]; Zeng et al., [@B43]; Bai et al., [@B1]; Yin et al., [@B40]), but other studies have found no such relationship (Jang et al., [@B17]; Wu et al., [@B35], [@B36], [@B34]; Glas et al., [@B10]; Lee et al., [@B20]; Lu et al., [@B21]; Kamangar et al., [@B19]; Garcia-Gonzalez et al., [@B9]; Hou et al., [@B15]; Crusius et al., [@B4]; Yang et al., [@B39]; Whiteman et al., [@B33]; Essadik et al., [@B7]; Xu et al., [@B38]). This inconsistency may be attributed to weak statistical power, small sample size, and clinical heterogeneity. Therefore, a meta-analysis was conducted to overcome the limitations of individual studies and clarify whether *TNF-*α rs361525 polymorphism conferred susceptibility to GC.

Materials and methods {#s2}
=====================

Literature search
-----------------

Two investigators systematically searched PubMed, Elsevier, EMBASE, and CNKI through Oct 5, 2017 to identify relevant studies using the following search terms: "Gastric Neoplasm," "Stomach Cancer," "Gastric Cancer," "Gastric Carcinoma," "Gastric Adenocarcinoma," "tumor necrosis factor alpha," "*TNF-*α," "polymorphism," "SNP," and "variant." In addition, all cited references were reviewed to find out studies that were not included in the above electronic databases. When two studies overlapped, we chose the latest study or the one with larger sample size. There was no restriction on language, ethnicity or region of study population. GC was diagnosed according to classification criteria.

Inclusion and exclusion criteria
--------------------------------

Inclusion criteria were: (1) evaluation of relationship between GC risk and TNF-α rs361525 polymorphism; (2) study on humans; (3) provision of enough data for computation of odds ratios (ORs) and 95% confidence intervals (CIs); (4) case- control study. Exclusion criteria were: (1) duplication; (2) case report or review; (3) lack of genotype data; (4) irrelevant topic.

Data extraction and quality assessment
--------------------------------------

From each included study, data including name of first author, country of origin, publication year, ethnicity, age, and genotype numbers in cases and controls was extracted. When more than one ethnicity were involved, genotype data was processed separately. Data extraction and study quality assessment based on the Newcastle-Ottawa Scale (NOS) (Stang, [@B27]) were conducted by two investigators independently. The NOS score varies from 0 up to 9: high-quality study: \>7; medium-quality study: 4--6; poor-quality study: \<4. All conflicting information was discussed and resolved with consensus.

Genotype and gene expression correlation analysis
-------------------------------------------------

Genotype data of TNF-α rs361525 polymorphism and its mRNA expression data were available from the International HapMap Project and GTex portal (<https://www.gtexportal.org/home/>), respectively (Gong et al., [@B11]).

Statistical analysis
--------------------

The strength of relationship between GC risk and *TNF-*α rs361525 polymorphism was investigated by using crude ORs and 95%CIs. The following comparisons for this relationship were made: the dominant model (AA+GA vs. GG), the recessive model (AA vs. GA+GG), the heterozygote model (GA vs. GG), the homozygote model (AA vs. GG), and the allele model (A vs. G). Stratification analyses were carried out by ethnicity, source of control (SOC), Hardy-Weinberg equilibrium (HWE), genotyping method and NOS score (He et al., [@B12]). The null hypothesis that all studies evaluated the same effect was tested by Cochran\'s Q-statistics. When significant heterogeneity was found (*P* \> 0.10 or I^2^ \> 50%), a random-effect model was used; otherwise, a fixed-effect model was applied (Higgins and Thompson, [@B14]). Sensitivity analysis was conducted by omitting one study at a time to test the relative influence on the pooled estimate. The significant findings were evaluated by calculating false-positive report probability (FPRP). An FPRP threshold of 0.2 and a prior probability of 0.1 were set to detect an OR for a correlation with the tested genotype. FPRP \<0.2 implied a significant relationship (He et al., [@B13]). χ^2^ test was carried out to clarify whether the observed genotype frequencies conformed to the HWE. Potential publication bias was examined by Begger\'s and Egger\'s linear regression tests (Wassen and Jertborn, [@B32]), with the significant level at *P* \< 0.05. All statistical analyses were conducted on Stata 11.0 (StataCorp, College Station, USA).

Results {#s3}
=======

Study characteristics
---------------------

The process of study selection is shown in Figure [1](#F1){ref-type="fig"}. The initial search returned 125 studies. Of them, 10 duplicates and 56 papers unrelated to the topic based on their abstracts and titles were excluded. Among the remaining 59 papers: 2 papers did not meet inclusion criteria; 27 papers investigated other polymorphisms; 1 paper 1 paper was not case-control study; 1 paper did not provide enough data. Finally, 20 4,084 cases and 7,010 controls were included. Of them, 12 articles were from Asian populations (Jang et al., [@B17]; Wu et al., [@B35], [@B36], [@B34]; Lee et al., [@B20]; Lu et al., [@B21]; Xing et al., [@B37]; Zeng et al., [@B43]; Bai et al., [@B1]; Yang et al., [@B39]; Yin et al., [@B40]; Xu et al., [@B38]) and 8 from Caucasian populations (Glas et al., [@B10]; Zambon et al., [@B42]; Kamangar et al., [@B19]; Garcia-Gonzalez et al., [@B9]; Hou et al., [@B15]; Crusius et al., [@B4]; Whiteman et al., [@B33]; Essadik et al., [@B7]). Six studies failed to obey HWE (Wu et al., [@B35], [@B36], [@B34]; Kamangar et al., [@B19]; Garcia-Gonzalez et al., [@B9]; Whiteman et al., [@B33]). The details of the included studies are presented in Table [1](#T1){ref-type="table"}. The year of publication ranged from 2001 to 2012. The numbers of cases and controls ranged from 52 to 404 and from 74 to 1,299, respectively.

![Selection for eligible papers included in this meta-analysis.](fphys-09-00469-g0001){#F1}

###### 

Characteristics of included studies.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Author and year**             **Gender (Female/Male)**   **Age**   **SOC**       **Nationality**   **Ethnicity**   **Case/Control**   **Genotyping method**   **HWE**    **NOS**                
  ------------------------------- -------------------------- --------- ------------- ----------------- --------------- ------------------ ----------------------- ---------- ------------ --------- ---
  Jang et al., [@B17]             N/A                        N/A       N/A           N/A               HB              Korea              Asian                   52/92      PCR-RFLP     0.391     6

  Wu et al., [@B35]               N/A                        N/A       N/A           N/A               HB              Taiwan             Asian                   150/220    Sequencing   \<0.001   5

  Wu et al., [@B36]               84/136                     88/142    60.9 ± 12.6   60.7 ± 13.4       HB              Taiwan             Asian                   220/230    Sequencing   \<0.001   6

  Glas et al., [@B10]             71/74                      41/47     65 ± 12.5     45 ± 12.5         HB              Germany            Caucasian               145/88     PCR-RFLP     0.635     6

  Lee et al., [@B20]              142/199                    123/138   46.0 ± 12.6   48.7 ± 10.9       HB              Korea              Asian                   341/261    Sequencing   0.416     6

  Wu et al., [@B34]               78/126                     84/126    60.1 ± 12.1   58.7 ± 14.4       HB              Taiwan             Asian                   204/210    Sequencing   \<0.001   6

  Lu et al., [@B21]               67/183                     83/217    59.0 ± 12.3   59.1 ± 9.4        PB              China              Asian                   250/300    DHPLC        0.49      7

  Zambon et al., [@B42]           N/A                        N/A       N/A           N/A               HB              Italy              Caucasian               129/644    TaqMan       0.378     6

  Kamangar et al., [@B19]         N/A                        N/A       N/A           N/A               PB              Finland            Caucasian               210/115    TaqMan       \<0.001   7

  Zambon et al., [@B42]           60/70                      72/70     58.6 ± 13.3   53.5 ± 11.2       HB              China              Asian                   130/142    gene chip    0.23      6

  Hou et al., [@B15]              103/202                    152/275   \<50 39\      \<50 52\          PB              Poland             Caucasian               299/412    TaqMan       0.492     6
                                                                       50--59 56\    50--59 75\                                                                                                     
                                                                       60--69 120\   60--69 168\                                                                                                    
                                                                       ≥70 90        ≥70 132                                                                                                        

  Garcia-Gonzalez et al., [@B9]   146/258                    138/266   73.7 ± 10.3   71.3 ± 12.0       HB              Spain              Caucasian               404/404    TaqMan       0.011     6

  Zeng et al., [@B43]             60/70                      72/70     59.0 ± 13.0   54.0 ± 11.0       HB              China              Asian                   130/142    gene chip    0.23      7

  Crusius2008                     N/A                        N/A       N/A           N/A               PB              Europe             Caucasian               235/1123   TaqMan       0.367     8

  Yang et al., [@B39]             25/59                      100/236   ≤ 63 43\      ≤63 176\          PB              Korea              Asian                   83/331     SNaPshot     0.457     6
                                                                       \>63 41       \>63 160                                                                                                       

  Bai et al., [@B1]               50/64                      56/63     58.3 ± 12.5   55.9 ± 14.9       HB              China              Asian                   114/119    gene chip    0.668     6

  Whiteman et al., [@B33]         22/247                     459/896   \<49 21\      \<49 216\         PB              Australia          Caucasian               289/1299   gene chip    0.007     7
                                                                       50--59 75\    50--59 348\                                                                                                    
                                                                       60--69 103\   60--69 480\                                                                                                    
                                                                       70--79 70     70--79 311                                                                                                     

  Yin et al., [@B40]              N/A                        N/A       N/A           N/A               HB              China              Asian                   310/485    SNaPshot     0.369     6

  Essadik et al., [@B7]           N/A                        N/A       N/A           N/A               PB              Morocco            Caucasian               93/74      Sequencing   0.978     7

  Xu et al., [@B38]               169/127                    180/139   44.0 ± 16.6   44.3 ± 15.9       HB              China              Asian                   294/319    PCR-RFLP     0.466     6
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*SOC, source of controls; PB, population-based controls; HB, hospital-based controls; NOS, Newcastle-Ottawa Scale; HWE, Hardy--Weinberg equilibrium; PCR-RFLR, PCR-restriction fragment length polymorphism; DHPLC, Denaturing high-performance liquid chromatograph*.

Quantitative analysis
---------------------

The results concerning the relationship between *TNF-*α rs361525 polymorphism and GC risk were summarized in Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}. This relationship was insignificant in the overall population (A vs. G: OR, 1.06; 95%CI, 0.83--1.35, *P* = 0.646, Figure [2](#F2){ref-type="fig"}). Stratification analyses of ethnicity indicated *TNF-*α rs361525 polymorphism intensified the risk of GC among Asians in most of the comparisons (AA+GA vs. GG: OR, 1.46; 95%CI, 1.11--1.91, *P* = 0.007, Figure [3](#F3){ref-type="fig"}), but decreased the risk among Caucasians in the allele and dominant models (AA+GA vs. GG: OR, 0.73; 95% CI, 0.54--0.99, *P* = 0.043, Table [3](#T3){ref-type="table"}). Subgroup analyses by genotyping methods revealed increased risk for other methods (A vs. G: OR, 1.54; 95%CI, 1.04--2.30, *P* = 0.033, Figure [4](#F4){ref-type="fig"}) and this relationship also held true in the HWE-positive studies. Stratified analysis by SOC did not find significant correlation in the hospital- or population-based studies (Table [3](#T3){ref-type="table"}). Similar results were observed in the subgroup analysis of NOS score.

###### 

Meta-analysis of association between TNF-α rs361525 polymorphism and gastric cancer.

  **Comparison**   **OR(95%CI)**     ***P*-value**   ***[^a^](#TN1){ref-type="table-fn"}P*-value**   ***P* for heterogeneity**   **I^2^ (%)**   **Model**
  ---------------- ----------------- --------------- ----------------------------------------------- --------------------------- -------------- -----------
  A vs. G          1.06(0.83,1.35)   0.646           1.000                                           \<0.001                     66.2           Random
  AA+GA vs. GG     1.06(0.83,1.36)   0.657           1.000                                           \<0.001                     63.1           Random
  AA vs. GA+GG     1.14(0.70,1.85)   0.782           0.782                                           0.053                       42.4           Fixed
  AA vs. GG        1.12(0.69,1.83)   0.644           1.000                                           0.047                       43.5           Fixed
  GA vs. GG        1.05(0.81,1.34)   0.733           0.917                                           \<0.001                     60.2           Random

*P values were calculated by a multiple comparison of Bonferroni correction*.

###### 

Summary of the subgroup analyses in this meta-analysis.

  **Comparisons**   **Category**   **Category**    **Studies**   **OR (95% CI)**        ***P*-value**   ***P* for heterogeneity**   **I^2^(%)**
  ----------------- -------------- --------------- ------------- ---------------------- --------------- --------------------------- -------------
  A vs. G           Ethnicity      Asian           12            **1.46(1.16, 1.85)**   0.002           0.054                       32.8
                                   Caucasian       8             **0.72(0.53, 0.99)**   0.043           0.106                       56.4
                    SOC            HB              13            1.26(0.97, 1.64)       0.084           0.117                       55.3
                                   PB              7             0.77(0.49, 1.22)       0.271           0.265                       77.2
                    HWE            Positive        14            1.19(0.90, 1.59)       0.226           0.183                       65.7
                                   Negative        6             0.76(0.57, 1.00)       0.051           0.019                       14.8
                    Genotyping     PCR-RFLR        3             0.80(0.35, 1.80)       0.582           0.299                       58.6
                                   Sequencing      5             0.80(0.45, 1.43)       0.455           0.223                       53.7
                                   TagMan          5             0.86(0.62, 1.19)       0.355           0.063                       47.8
                                   Other methods   7             **1.54(1.04, 2.30)**   0.033           0.200                       71.1
                    NOS score      5 ≤ Score ≤ 6   14            1.22(0.97, 1.53)       0.054           0.047                       42.5
                                   Score \> 6      6             0.75(0.41, 1.37)       0.185           \<0.001                     83.2
  GA+AA vs. GG      Ethnicity      Asian           12            **1.46(1.11, 1.91)**   0.007           0.086                       40.4
                                   Caucasian       8             **0.73(0.54, 0.99)**   0.043           0.082                       47.3
                    SOC            HB              13            1.25(0.95, 1.65)       0.111           0.122                       52.6
                                   PB              7             0.79(0.50, 1.24)       0.301           0.253                       69.6
                    HWE            Positive        14            1.16(0.85, 1.57)       0.357           0.216                       67.0
                                   Negative        6             0.80(0.62, 1.04)       0.095           \<0.001                     0.0
                    Genotyping     PCR-RFLR        3             0.81(0.36, 1.83)       0.606           0.291                       56.8
                                   Sequencing      5             0.80(0.42, 1.50)       0.479           0.262                       51.8
                                   TagMan          5             0.87(0.66, 1.15)       0.333           0.025                       24.1
                                   Other methods   7             1.53(0.99, 2.36)       0.054           0.243                       72.6
                    NOS score      5 ≤ Score ≤ 6   14            1.20(0.95, 1.50)       0.120           0.105                       33.8
                                   Score \>6       6             0.77(0.41, 1.45)       0.414           \<0.001                     82.8
  AA vs. GA+GG      Ethnicity      Asian           7             **2.41(1.16, 4.98)**   0.018           0.300                       17.1
                                   Caucasian       6             0.51(0.23, 1.12)       0.095           0.040                       57.2
                    SOC            HB              8             1.50(0.84, 2.67)       0.172           0.021                       57.5
                                   PB              5             0.53(0.19, 1.48)       0.226           0.673                       0.0
                    HWE            Positive        7             **3.82(1.69, 8.61)**   0.001           0.172                       33.6
                                   Negative        6             **0.45(0.21, 0.93)**   0.031           0.457                       0.0
                    Genotyping     PCR-RFLR        1             0.58(0.02, 14.52)      0.741           N/A                         N/A
                                   Sequencing      4             0.86(0.33, 2.25)       0.761           0.835                       0.0
                                   TagMan          4             0.61(0.26, 1.42)       0.247           0.012                       72.5
                                   Other methods   4             **3.43(1.37, 8.61)**   0.009           0.127                       47.4
                    NOS score      5 ≤ Score ≤ 6   8             1.50(0.84, 2.67)       0.172           0.021                       57.5
                                   Score\>6        5             0.53(0.19, 1.48)       0.226           0.673                       0.0
  AA vs. GG         Ethnicity      Asian           7             **2.41(1.17, 4.98)**   0.018           0.291                       18.3
                                   Caucasian       6             0.50(0.23, 1.10)       0.084           0.039                       57.4
                    SOC            HB              8             1.50(0.84, 2.67)       0.171           0.021                       57.6
                                   PB              5             0.51(0.18, 1.43)       0.199           0.641                       0.0
                    HWE            Positive        7             **3.68(1.64, 8.28)**   0.002           0.146                       37.0
                                   Negative        6             **0.44(0.21, 0.92)**   0.029           0.446                       0.0
                    Genotyping     PCR-RFLR        1             0.53(0.02, 13.30)      0.700           N/A                         N/A
                                   Sequencing      4             0.85(0.33, 2.21)       0.740           0.794                       0.0
                                   TagMan          4             0.60(0.26, 1.40)       0.236           0.013                       72.4
                                   Other methods   4             **3.40(1.36, 8.47)**   0.009           0.121                       48.4
                    NOS score      5 ≤ Score ≤ 6   8             1.50(0.84, 2.67)       0.171           0.021                       57.6
                                   Score\>6        5             0.51(0.18, 1.43)       0.199           0.641                       0.0
  GA vs. GG         Ethnicity      Asian           12            **1.40(1.03, 1.91)**   0.032           0.032                       48.0
                                   Caucasian       8             0.76(0.57, 1.01)       0.057           0.115                       39.6
                    SOC            HB              13            1.21(0.90, 1.63)       0.210           0.011                       53.7
                                   PB              7             0.82(0.53, 1.26)       0.358           0.009                       64.9
                    HWE            Positive        14            1.09(0.80, 1.50)       0.585           \<0.001                     67.6
                                   Negative        6             0.87(0.66, 1.15)       0.322           0.466                       0.0
                    Genotyping     PCR-RFLR        3             0.84(0.38, 1.82)       0.651           0.651                       52.6
                                   Sequencing      5             0.80(0.39, 1.66)       0.553           0.553                       49.0
                                   TagMan          5             0.90(0.69, 1.16)       0.411           0.411                       7.6
                                   Other methods   7             1.43(0.91, 2.26)       0.120           0.120                       73.9
                    NOS score      5 ≤ Score ≤ 6   14            1.16(0.91, 1.47)       0.233           0.096                       34.9
                                   Score\>6        6             0.80(0.43, 1.48)       0.473           \<0.001                     80.8

*SOC, source of controls; PB, population-based controls; HB, hospital-based controls; NOS, Newcastle-Ottawa Scale; HWE, Hardy--Weinberg equilibrium; PCR-RFLR, PCR-restriction fragment length polymorphism. Bold values are statistically significant (P \< 0.05)*.

![Forest plot shows odds ratio for the association between TNF-α rs361525 polymorphism and GC risk (A vs. G).](fphys-09-00469-g0002){#F2}

![Stratification analyses of ethnicity between TNF-α rs361525 polymorphism and GC risk (AA+GA vs. GG).](fphys-09-00469-g0003){#F3}

![Stratification analyses of genotyping methods between TNF-α rs361525 polymorphism and GC risk (A vs. G).](fphys-09-00469-g0004){#F4}

TNF-α mRNA expression by genotypes
----------------------------------

The TNF-α mRNA expression levels by the genotypes of rs361525 polymorphism were significantly different for the whole blood (*P* = 5.10 × 10^−14^) and transformed fibroblasts (*P* = 6.65 × 10^−10^) (Figure [5](#F5){ref-type="fig"}).

![The TNF-α mRNA expression levels by the genotypes of rs361525 polymorphism.](fphys-09-00469-g0005){#F5}

Sensitivity and publication bias
--------------------------------

In the sensitivity analysis, no overall significant change was found when any single study was removed, suggesting our results are statistically robust. Neither Egger\'s nor Begg\'s tests (GA vs. GG, Figure [6](#F6){ref-type="fig"}) showed any evidence of publication bias in this meta-analysis.

![Begg\'s tests for publication bias between TNF-α rs361525 polymorphism and risk of GC (GA vs. GG).](fphys-09-00469-g0006){#F6}

FPRP analyses
-------------

The FPRPs for significant results at different *p* levels are shown in Table [4](#T4){ref-type="table"}. At the level of 0.1, some FPRPs were all \<0.20, indicating the significant associations between TNF-α rs361525 polymorphism and GC risk were noteworthy (Table [4](#T4){ref-type="table"}). However, the FPRPs for other significant associations were larger, suggesting some possible bias due to sample size reduction existed in some subgroups, which should be validated by larger-size studies in the future.

###### 

False-positive report probability values for associations between the TNF-α−238 polymorphism and gastric cancer risk.

  **Variables**          **OR(95%CI)**      ***P* value**   **Power**   **Prior Probability**                               
  ---------------------- ------------------ --------------- ----------- ----------------------- ----------- ------- ------- -------
  **A vs. G**                                                                                                               
  Asian                  1.46(1.16, 1.85)   0.002           0.605       **0.010**               **0.029**   0.247   0.768   0.971
  Caucasian              0.72(0.53, 0.99)   0.043           0.670       **0.161**               0.366       0.864   0.985   0.998
  Other methods          1.54(1.04, 2.30)   0.033           0.565       **0.149**               0.344       0.852   0.983   0.998
  **GA**+**AA vs. GG**                                                                                                      
  Asian                  1.46(1.11, 1.91)   0.007           0.603       **0.034**               **0.095**   0.535   0.921   0.991
  Caucasian              0.73(0.54, 0.99)   0.043           0.710       **0.154**               0.353       0.857   0.984   0.998
  **AA vs. GA**+**GG**                                                                                                      
  Asian                  2.41(1.16, 4.98)   0.018           0.543       **0.090**               0.230       0.766   0.971   0.997
  HWE-positive           3.82(1.69, 8.61)   0.001           0.497       **0.006**               **0.018**   0.166   0.668   0.953
  HWE-negative           0.45(0.21, 0.93)   0.031           0.624       **0.130**               0.309       0.831   0.980   0.998
  Other methods          3.43(1.37, 8.61)   0.009           0.522       **0.049**               0.134       0.630   0.945   0.994
  **AA vs. GG**                                                                                                             
  Asian                  2.41(1.17, 4.98)   0.018           0.543       **0.090**               0.230       0.766   0.971   0.997
  HWE-positive           3.68(1.64, 8.28)   0.002           0.529       **0.011**               **0.033**   0.272   0.791   0.974
  HWE-negative           0.44(0.21, 0.92)   0.029           0.628       **0.122**               0.293       0.820   0.979   0.998
  Other methods          3.40(1.36, 8.47)   0.009           0.531       **0.048**               **0.132**   0.627   0.944   0.994
  **GA vs. GG**                                                                                                             
  Asian                  1.40(1.03, 1.91)   0.032           0.661       **0.127**               0.304       0.827   0.980   0.988

*HWE, Hardy--Weinberg equilibrium*.

Discussion {#s4}
==========

It is hypothesized chronic inflammation plays a crucial role in the etiology of GC and other cancers. Epplein et al. found the upregulated circulating levels of inflammation-related cytokines such as TNF-α may intensify the risk of GC (Epplein et al., [@B6]). TNF-α-induced protein secretion from *H. pylori* is involved in the development of GC (Suganuma et al., [@B28]). It is assumed the stimulation of the TNF-α/TNFR1 signaling in the tumor microenvironment enhances GC progression by inducing Noxo1 and GNA14 (Oshima et al., [@B23]). TNF-α is a promising effective target for GC therapy. The *TNF-*α rs361525 polymorphism could change TNF-α gene transcription and adjust TNF-α generation (Kaluza et al., [@B18]).

Many studies have reported the relationship between *TNF-*α rs361525 polymorphism and GC risk (Jang et al., [@B17]; Wu et al., [@B35], [@B36], [@B34]; Glas et al., [@B10]; Lee et al., [@B20]; Lu et al., [@B21]; Zambon et al., [@B42]; Kamangar et al., [@B19]; Xing et al., [@B37]; Garcia-Gonzalez et al., [@B9]; Hou et al., [@B15]; Zeng et al., [@B43]; Crusius et al., [@B4]; Bai et al., [@B1]; Yang et al., [@B39]; Whiteman et al., [@B33]; Yin et al., [@B40]; Essadik et al., [@B7]; Xu et al., [@B38]), but with conflicting findings. Given such conflicts, several meta-analyses in this field have been conducted (Zhou et al., [@B44]; Yu et al., [@B41]; Rokkas et al., [@B25]; Hui et al., [@B16]). Zhou et al. firstly meta-analyzed the association between *TNF-*α rs361525 polymorphism and cancer risk (Zhou et al., [@B44]), but found no significant result in the general populations (Zhou et al., [@B44]) or in the subgroups of cancer type including GC (Zhou et al., [@B44]). The two subsequent meta-analyses also did not observe an association between *TNF-*α rs361525 polymorphism and GC risk (Rokkas et al., [@B25]; Hui et al., [@B16]). Noticeably, Hui et al. revealed *TNF-*α rs361525 polymorphism could significantly increase the risk of digestive system cancer, but not GC (Hui et al., [@B16]). However, Yu et al. uncovered a significant relationship between *TNF-*α rs361525 polymorphism and increased GC risk in Asians, but not in Caucasians (Yu et al., [@B41]). Recently, new studies in this field have emerged, which further necessitates a new comprehensive meta-analysis. Here our data are consistent with Yu et al. It is worth noting that we found a significant association of *TNF-*α rs361525 polymorphism with GC among both Asians and Caucasians in the stratified analysis by ethnicity, while Yu et al. did not find any association among Caucasians (Yu et al., [@B41]). We found *TNF-*α rs361525 polymorphism increased the risk of GC among Asians, while this SNP seemed to protect Caucasians from GC. There are several possible interpretations for the different findings between Asians and Caucasians. Firstly, GC may be genetically and clinically heterogeneous among different populations. Secondly, varying sample sizes of Asians and Caucasians may also account. The third reason may be the differences in genotyping methods and random errors. The fourth reason may be the varying prevalence of *H. pylori* among different populations. Last but not least, different geographical environments and dietary pattern may also be influential (such as Asians eat more pickled and fried food). We believe this meta-analysis has several strengths over previous meta-analyses. Firstly, our sample size was larger. Secondly, sensitivity analysis proved the reliability and stability of our data. Thirdly, we conducted subgroup analyses of ethnicity, HWE, SOC, NOS score, and genotyping methods, and explored the potential sources of heterogeneity. Finally, we calculated false-positive report probability and statistical power.

However, this study also has some limitations. Firstly, no subgroup analyses of confounding factors such as age, sex, smoking or *H. pylori* infection were conducted. Secondly, potential gene-gene or gene-environment interactions were not assessed. Thirdly, only one SNP of *TNF-*α gene was investigated. Finally, the relationship between this SNP and clinical manifestations of GC was not examined.

In conclusion, this meta-analysis indicates the *TNF-*α rs361525 polymorphism increases the risk of GC among Asians, but decreases the risk of GC among Caucasians. This finding should be validated by larger case-control studies in other ethnicities.
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